Advances and Perspectives in the Treatment of B-Cell Malignancies

Cuenca, Marta; Peperzak, Victor

doi:10.3390/cancers13092266

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since B-cell malignancies develop from different stages of development, these constitute a heterogeneous group of pathologies [106]. For this reason, they possess intra-and inter-patient differences that can significantly influence both the selection and the duration of the treatment [107].…”

Section: Therapeutic Approaches To B-cell Malignanciesmentioning

confidence: 99%

“…B-cell malignancies possess intra-and inter-patient differences that can significantly influence both the choice and duration of treatment [107]. In recent years, the focus was set on "next generation" treatments, capable of overcoming the typical limits of standard treatments, which have been effective but with a lot of limitations.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Grimaldi

Toffoli

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Nanoparticle-based therapies have been proposed in oncology research using various delivery methods to increase selectivity toward tumor tissues. Enhanced drug delivery through nanoparticle-based therapies could improve anti-tumor efficacy and also prevent drug resistance. However, there are still problems to overcome, such as the main biological interactions of nanocarriers. Among the various nanostructures for drug delivery, drug delivery based on polymeric nanoparticles has numerous advantages for controlling the release of biological factors, such as the ability to add a selective targeting mechanism, controlled release, protection of administered drugs, and prolonging the circulation time in the body. In addition, the functionalization of nanoparticles helps to achieve the best possible outcome. One of the most promising applications for nanoparticle-based drug delivery is in the field of onco-hematology, where there are many already approved targeted therapies, such as immunotherapies with monoclonal antibodies targeting specific tumor-associated antigens; however, several patients have experienced relapsed or refractory disease. This review describes the major nanocarriers proposed as new treatments for hematologic cancer, describing the main biological interactions of these nanocarriers and the related limitations of their use as drug delivery strategies.

show abstract

Section: Therapeutic Approaches To B-cell Malignanciesmentioning

confidence: 99%

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Grimaldi

Toffoli

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…1 Introduction B-cell neoplasms, which stem from distinct stages of B-cell development, are a heterogeneous set of cancers including B-cell lymphomas (BCLs), chronic lymphocytic leukemia (CLL), and plasma cell dyscrasias such as multiple myeloma (MM) (1). Despite great advances have been achieved in diagnosis and treatment, these hematologic disorders still cause significant global morbidity and mortality.…”

mentioning

confidence: 99%

Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

et al. 2022

View full text Add to dashboard Cite

Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide and pomalidomide are antitumor compounds that have direct tumoricidal activity and indirect effects mediated by multiple types of immune cells in the tumor microenvironment (TME). IMiDs have shown remarkable therapeutic efficacy in a set of B-cell neoplasms including multiple myeloma, B-cell lymphomas and chronic lymphocytic leukemia. More recently, the advent of immunotherapy has revolutionized the treatment of these B-cell neoplasms. However, the success of immunotherapy is restrained by immunosuppressive signals and dysfunctional immune cells in the TME. Due to the pleiotropic immunobiological properties, IMiDs have shown to generate synergetic effects in preclinical models when combined with monoclonal antibodies, immune checkpoint inhibitors or CAR-T cell therapy, some of which were successfully translated to the clinic and lead to improved responses for both first-line and relapsed/refractory settings. Mechanistically, despite cereblon (CRBN), an E3 ubiquitin ligase, is considered as considered as the major molecular target responsible for the antineoplastic activities of IMiDs, the exact mechanisms of action for IMiDs-based TME re-education remain largely unknown. This review presents an overview of IMiDs in regulation of immune cell function and their utilization in potentiating efficacy of immunotherapies across multiple types of B-cell neoplasms.

show abstract

Zanubrutinib: a breakthrough in cancer therapy targeting Bruton’s tyrosine kinase, originating from China, and benefiting the global community

Zhang,

Song,

Liu

et al. 2025

Drug Discovery Stories

View full text Add to dashboard Cite

Advances and Perspectives in the Treatment of B-Cell Malignancies

Abstract: B-cell malignancies arise from different stages of B-cell differentiation and constitute a heterogeneous group of cancers including B-cell lymphomas, B-cell leukemias, and plasma cell dyscrasias [...]

Cited by 5 publications

References 18 publications

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies

Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

Zanubrutinib: a breakthrough in cancer therapy targeting Bruton’s tyrosine kinase, originating from China, and benefiting the global community

Contact Info

Product

Resources

About